Physician profile
Gregory Sutton
NPI 1568409373
$7,960.93
in general payments reported to CMS, 2019-2025
20 companies · $2,968 in 2025
The $2,968 reported for 2025 was more than what 82% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $223 · 2021: $215 · 2022: $169 · 2023: $3,550 · 2024: $166 · 2025: $2,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,165 · Food and Beverage: $438 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,165.00 |
| Food and Beverage | $438.24 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,636.17 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $359.34 | 2019-2025 | Jemperli, Zejula |
| Intuitive Surgical, INC. | $334.66 | 2019-2022 | |
| Genentech USA, INC. | $98.84 | 2019 | |
| Karyopharm Therapeutics INC. | $76.86 | 2022 | |
| Beone Medicines USA, INC. | $75.41 | 2025 | Tevimbra |
| Merck Sharp & Dohme LLC | $55.02 | 2019-2024 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $44.61 | 2019 | |
| Seagen INC. | $43.37 | 2022 | |
| Tersera Therapeutics LLC | $40.48 | 2019 | |
| Genzyme Corporation | $39.74 | 2019 | |
| Janssen Biotech, INC. | $36.00 | 2025 | Darzalex, Talvey |
| Celgene Corporation | $22.89 | 2019 | |
| Eisai INC. | $21.59 | 2019 | |
| Lilly USA, LLC | $17.68 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $17.56 | 2019 | |
| Baxter Healthcare | $15.59 | 2019 | |
| Amgen INC. | $15.18 | 2020 | |
| Fortovia Therapeutics, INC. | $9.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.